Cgix presentation red chip

RedChip Global Conference
Company & Portfolio Update
Wednesday, October 15, 2014

Company & Portfolio Update | 2014 Cancer Genetics, Inc. | www.cancergenetics.com
Forward-Looking Statement
2
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services or Gentris, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward- looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks related to integration of the acquisitions of Gentris and BioServe and the realization of the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended June 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward- looking statements.

Who We Are…A Brief Overview of Our Business
3
Develop and commercialize unique, genomic tests for comprehensive assessment and personalization of cancer
Provide this for areas of high unmet need and with a business model centered around providing these tests as a service to both clinical centers and hospitals as well as for the biotech and pharma companies
Business Focus
Locations in New Jersey, North Carolina, India and China with 170 employees globally
Agreements with Roche, Gilead, Astra Zeneca & other biotechs
Joint Venture with Mayo Clinic in NGS, OncoSpire Genomics
16 research collaborations with leading institutions
Six launched products
Business Basics

Clinical Biopharma
4
$6 Bn
$2.5 Bn
$0.4 Bn
$1 Bn
$1 Bn
N/A
US India
China
We Are Positioned To Be The Leader In Attractive Markets With Significant Needs In Oncology

Our Core Areas of Expertise – Multiple Products Launched
5

6
Validation & Collaboraton With Leading Academic &
Research Partners Is The Backbone Of Our Unique Model

Proprietary Programs Drive Value for Both Biotech &
Pharma Clients and the Clinical Community CGI Is Uniquely Positioned From Bench to Bedside Discovery BiopharmaClinical
7

Unique Footprint To Be A Global Partner in the Personalization of Cancer Treatment
~170 People Focused on Oncology Genomics & Biomarkers For The Personalization of Medicine
Rutherford, NJ 18,000 sq. ft.
Raleigh, NC
28,000 sq. ft.
Hyderabad, India
14,000 sq. ft.
Shanghai, China 4,000 sq. ft.
8

Major Drivers for our Proprietary Programs
Is There Unmet Patient Need Is It Unique & Can It Drive An “IP”-Ready Position Can We Leverage The Existing, Routine Sample Can We Validate & Collaborate w. Major Research Centers Offer As A Part Of Our “Complete” Programs
9

6 Proprietary Diagnostic Products Commercially Launched & In Market
10
Incidence
Indication
Hematologic Cancers
106,770
(Annual New Cases, Global)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
142,360
Diffuse Large B-Cell Lymphoma
62,300
Follicular Lymphoma
17,795
Mantle Cell Lymphoma
Urogenital Cancers
274,000
Kidney Cancer
HPV-Associated Cancers
(FHACT®)
1,750,000
(Annual New Cases, US)
HPV-Associated Cervical Cancer
Over 2.3 Mn Combined Annual New Cases Globally

Product Pipeline
11
Research &
Discovery
Clinical
Development
Commercial
Development
Launch &
Market Entry
Indication
Development Stage
Hematologic Cancers
Multiple Myeloma
Comprehensive Myeloid Panel
[NGS-based]
Comprehensive CLL Panel
[NGS-based]
UroGenital Cancers
Bladder Cancer
Comprehensive Renal Panel
[NGS-based]
Cervical Cancer
HPV-Associated Cancers
(FHACT®)
Head & Neck Cancer

Cervical cancer remains a public health challenge and
several unmet needs continue to emerge in the battle
In industrialized countries, screening programs are VERY costly and NOT highly accurate.
Colposcopy-guided biopsy cost ranges $600-1,200 and delays diagnosis and treatment.
HPV testing does not make use of somatic genome and does not necessarily indicate presence of cancer
2
Several tests are available but the need for less invasive and better informed treatment exists
* Transparency Market Research
3
1
Cervical cancer remains a worldwide public health challenge, especially in developing countries – often diagnosed too late.
85% of incidence correspond to developing countries
Cervical cancer Dx test is estimated to reach USD 75 Mn globally in 2018*.
GLOBOCAN 2012 (IARC)
WORLDWIDE
528,000 cases diagnosed per year
266,000 deaths (7.5% all female cancer)
FHACT® | 2014 Cancer Genetics, Inc. | www.cgifhact.com | www.cancergenetics.com
4

FHACT® fits directly into today’s cervical cancer screening workflow as an additional triage prior to colposcopy
Today, all these women are referred for colposcopy.
Doesn’t need colposcopy now.
Referred for colposcopy.
PROGRESS to a higher grade and increased risk for cancer within 10-30 years of the infection.
REGRESS within 2 years of the infection.
Abnormal signal pattern
HPV+ women with abnormal or unclear liquid-based cytology.
Normal signal pattern
Unmet Clinical Need Identify women with low grade cervical/ undetermined lesions that will progress to a higher grade versus those that will regress. CGI Solution FISH-based HPV-Associated Cancer Test Include FHACT® as additional triage before referral for colposcopy.
No resampling
Fewer women referred for colposcopy
Reduced healthcare costs
13

FHACT® can aid in identifying women with markers of high grade lesions (cervical cancer)
FISH-based HPV-Associated Cancer Test FHACT® assesses non-random genomic alterations associated with progression of lesion.
Gain of 3q26 (TERC) has been detected with increasing frequency in cervical lesions with increasing severity and ultimately is observed in about 75% of cervical cancers.[1-2]
Gains of 5p15, 20q13 & chromosome 7 share a similar pattern of appearance in precancerous cytology specimens by FISH (40- 45% for 5p15 and 20q13, and 15% for chromosome 7).[3-4]
Performed on remnant liquid based cytology (LBC). FHACT® presents the highest sensitivity on the market (4 loci). Gain at any of the FHACT® loci is detected in up to 89.5% of all cervical cancers.[5]
1.Heselmeyer-Haddad K, et al. (2005). Am. J. Pathol. , 166, 1229-1238
2.Seppo A., et al. (2009) Gynecol Oncol, 114, 80-83
3.Scotto, L., et al. (2008). Mol Cancer, 7, 58. 4. Luhn P, et al. (2013). Gynecol Oncol, 130, 595-600. 5. The Cancer Genome Atlas (TCGA) (http:/cancergenome.nih.gov)
chromosome 3
chromosome 7
chromosome 5
chr 20
14
FHACT® Loci:
3q26 gain (red)
5p15 gain (green)
Cen7 (aqua)
20q13 gain (gold)

Renal Portfolio | 2014 Cancer Genetics, Inc. | www.cancergenetics.com
15,720 new cases 4,600 deaths
Estimated for 2014 [ACS]
Unmet Needs:
Risk stratification to identify patients most likely to have aggressive disease.
Therapy selection
Chronic Lymphocytic Leukemia (CLL)
Median age at diagnosis is 65 to 68 years
Overall median survival is 9 years
Approximately 10% of all adult hematologic malignancies (40% of leukemias in individuals over 65 years of age)
Two roughly equal clinical subtypes: indolent & aggressive
15
Hematology Portfolio | 2014 Cancer Genetics, Inc. | www.cancergenetics.com
7-8x That Are Living With CLL

Comprehensive Genomic Evaluation of CLL For Improved Diagnosis and Prognosis
13q loss 12 gain 1p gain 4p loss 5p loss 6q loss 7p loss 7p gain 18p gain 18q gain 19p gain 17p loss 11q loss 2p gain 3q gain 7q loss 8p loss 8q gain 17q gain 18p loss
Favorable Intermediate Unfavorable
Favorable/ Intermediate (no distinction)
38% of cases in our study have a favorable prognosis falling under "watch & wait" approach.
8% of cases with unfavorable prognosis missed by FISH and caught using MatBA®-CLL/SLL.
Impact on therapy selection & clinical management of CLL patients.
Genomic Aberrations Reported Genomic Aberrations Reported by FISH: by MatBA®-CLL/SLL: 4 20
85%
15%
23%
39%
FISH (Current Method)
38%
(CGI Method)
13q loss 12 gain 17p loss 11q loss
16

Independent Validation Datasets: DFCI (124), HUMC (65)
Time to First Treatment (TTFT)
Time (months)
Time (months)
Proportion Surviving
Proportion Treatment- Free
– GOOD (n=74)
– INTERMED (n=107)
– POOR (n=47)
– GOOD (n=74)
– INTERMED (n=107)
– POOR (n=47)
P = 0.090
P = 0.001
P < 0.001
P = 0.010
Overall Survival (OS)
Leukemia & Lymphoma – Houldsworth, et. al Sept. 18, 2013
Time (months)
TTFT: DFCI
Proportion Treatment-Free
P<0.001
Good (n=63) Intermediate (n=47) Poor (n=14)
Time (months)
OS: DFCI
P=0.522
Time (months)
TTFT: HUMC
Proportion Treatment-Free
P=0.039
Time (months)
OS: HUMC
P=0.044
[Jennifer Brown]
[Anthony Mato]
Discovery: 288 specimens
Validation: 124, 65 specimens
17

Significance of Current Prognostication Markers in CLL in the B-Cell Receptor Signaling Pathway Inhibitor Era
B-Cell Receptor Signaling Pathway Inhibitors
[Kanti Rai, Nicholas Chiorazzi, Jacqueline Barrientos]
Zydelig [Idelalisib (PI3K-delta)]
FDA Approved For CLL in the relapse setting when considering Rituximab alone
Collaborative project in progress at CGI
Inisights will be integrated into our Complete CLL
IMBRUVICA® [Ibrutinib (BTK)]
FDA Approved for CLL with 17p loss and in the relapse setting where two prior therapies have failed
Genomic alterations associated with resistance
Acquired Mutations during therapy in BTK Gene (C481S), PLCG2 (R665W)
Deletion of 8p
Gain of 3q
18

$1 M funded in 2013 to initiate Joint Venture & Another $1M in 2014
Up to $4 M in additional funding based on project milestones
Projects Have 12 to 30 month development horizon
Core operations based in Rochester, MN and leverage Mayo facilities
World class NGS facility
Best in class bioinformatics
Globally leading clinicians
Immediately integrated into care
Scientific leadership
Disease focus and stewardship
Commercial focus and management
Capital access and investment
19
OncoSpire Genomics | 2014 Cancer Genetics, Inc. | www.cancergenetics.com

OncoSpire Genomics: Projects are Unique and Have High Value
20
1.6 million new cases
200,000 new cases
20,920 new cases
Informed Discovery
Clinical Development
Commercial Development
Market Entry (with partners)
Lung Cancer
Multiple Myeloma
Follicular Lymphoma
Selected Projects Have Significant Clinical Value & May Yield Multiple Focused Panels to Become the Standard of Care in NGS-Based Oncology Management

Multiple Myeloma Two Essential Needs Can Be Met
21
Earlier, More Accurate, Cost-Effective Prediction of MM  Identify mutations that predict change from MGUS to MM
Provide Greater Certainty & Reduce Complexity of Diagnosis  Replaces cytogenetics, FISH and gene expression profiling
Two NGS-based tests will be developed to…
To target a major unmet need that is growing globally: Identifying MGUSs that need follow-up & treatment and determining best treatments for malignancies
1.
2.

Multiple Myeloma: Setting the New Standard with a Focused NGS Panel
22
77 genes selected for panel
DNA sequencing complete for first 60 samples
Analysis underway comparing 3 different analytical methods to determine best solution
In process of optimizing clinical laboratory design from extraction to reporting solution
3 papers in the publication process
2 international early-access collaborations established

Strong History of Growth CGI Revenue & Clinical Volume Trends (2009 – 2013)
23
54% Full Year 2013 Revenue Growth
$1.67
$2.52
$3.02
$4.30
$6.61
2009
2010
2011
2012
2013
2,321
3,146
3,622
6,610
10,771
2009
2010
2011
2012
2013
Total Revenue ($Mn)
Clinical Volume (Tests Processed)

Strong History of Growth Revenue & Clinical Volume Trends (Q2 Comparison 2012-2014)
24
Total Revenue ($Mn)
Clinical Volume (Tests Processed)
$1,148
$1,832
$3,231
Q2, 2012
Q2, 2013
Q2, 2014
1,623
3,204
2,664
Q2, 2012
Q2, 2013
Q2, 2014
Combined CGI & Gentris Revenue

Summary Statement of Operations (1st Half Comparison 2012-2014)
25
Income Statement Item
1H, 2012
1H, 2013
1H, 2014
Combined 1H, 2014*
Revenue
$1,983
$3,050
$2,942
$6,508
Gross Profit
74
701
149
1,781
Gross Margin (%)
3.7%
23.0%
5.1%
27.4%
Research & Development (R&D)
1,050
951
1,703
2,043
Sales & Marketing (S&M)
716
832
1,667
1,703
General & Administrative (G&A)
2,329
2,961
5,127
7,092
Operating Profit (Loss)
(4,021)
(4,043)
(8,348)
(9,056)
Net Income (Loss)
(2,933)
(6,782)
(6,673)
(7,417)
$ in thousands
* The “Combined 1H, 2014” results are the aggregation of first half 2014 of both Cancer Genetics, Inc. and Gentris Corporation. The amounts may not be indicative of future results.
Actual 06/30/14
All Cash*
$43,418
Stockholders’ Equity
40,463
$ in thousands * All cash included $6,000 restricted to collateralize a credit line
Balance Sheet Information

Multiple Customer Types Provide Diversified Revenue Mix With Covered Lives Already in Place
26
Selected Payors
Direct Bill Customer Types
Biotechs
Pharmas
Academic
Cancer Facilities
Community & Regional Labs
72+ million covered lives through multiple payors:
18%
21%
58%
3%
Medicare
3rd Party Insurance
Companies, Hospitals & Care Facilities
Payor Revenue Mix 1H, 2014
Reimbursement Based
Direct Bill / Pay Based
3rd Party Insurance
Medicare
1H, 2014
Probes
Companies, Hospitals
& Care Facilities

Consistent Achievement of Milestones Expected in Coming Quarters
27
Increasing covered lives market access through additional payers & health care organizations
Launching multi-marker NGS panel for lymphoid malignancies
Additional international agreements with life science tools companies for DNA Probes and product distribution in key geographies
MatBA® – Next phase of data and results from Dana Farber and HUMC studies to help support value and reimbursement
Pursuing CE approval for IVDD use of FHACT® in E.U.
Additional news on biopharma partners & relationships
Pursuing additional indications for UroGenRA®-Kidney microarray
Close of BioServe transaction (Q3, 2014)
Migrated DNA-FISH Probe Manufacturing to India reducing cost, increasing capacity and improving operational flexibility
Launched UroGenRA®-Kidney, a unique microarray for kidney cancer diagnosis in collaboration with MSKCC
Collaborative Study of UroGenRA®-Kidney with Cleveland Clinic demonstrated 93% diagnostic accuracy – announced results at the AACR 105th Annual Meeting
Launched FHACT® outside the U.S. in collaboration with the National Cancer Institute research publication and in the U.S. as an LDT under CLIA
Promoted FHACT® at the ACOG Annual Meeting
Received CLIA Approval for MatBA®-MCL (Mantle Cell Lymphoma)
Finalized Agreement with Multiplan and Three Rivers which gave us access to 72+ million covered lives
Launched OncoSpire Genomics – A Next Generation Sequencing Joint Venture with Mayo Clinic and announced initial set of projects (lung cancer, multiple myeloma & follicular lymphoma)
Launched CALR Mutation Test – for the diagnosis of myeloproliferative neoplasms potentially evolving into acute leukemia
Announced Multi-Year PathAdvantage Collaboration – for FHACT® (cervical cancer)
Partnered with AstraZeneca – CGI will provide biomarker-based Dx in Central America and the Caribbean
Acquisition of Gentris Corporation – closed on July 16, 2014
Recent
Accomplishments
Upcoming Milestones and Value Drivers

Experienced and Focused Management and Boards
28
Scientific Advisory Board
Andrea Califano, Ph.D.
Chairman of the Columbia Initiative for Systems Biology
Associate Director for Bioinformatics, Herbert Irving Comprehensive Cancer Ctr
Timothy A. Chan, M.D., Ph.D.
Principal Investigator, Human Oncology and Pathogenesis Program at Memorial Sloan- Kettering Cancer Center
Riccardo Dalla-Favera, M.D.
Director, Institute for Cancer Genetics at Columbia University
Vundavalli V. Murty, Ph.D.
Director, Cancer Cytogenetic Laboratory and Molecular Pathology at Columbia University
Hans-Guido Wendel, M.D.
Principal Investigator, Cancer Genetics Laboratory at Memorial Sloan-Kettering Cancer Center
Howard McLeod, PharmD
Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
Andrew D. Zelenetz, M.D., Ph.D.
Chief of Lymphoma Service and Head of Molecular Hemo-Oncology Laboratory, Department of Medicine at MSKCC
Raju Chaganti, Ph.D., FACMG Founder
•35+ years in cancer research; 38 at MSKCC
•Major discoveries in cancer genomics
•Published 350+ articles, 4 patents
Panna Sharma President & CEO
•15+ years as advisor to global life science & healthcare cos.
•Founded TSG Partners
•Chief Strategy Officer, iXL (IIXL)
Edward J. Sitar Chief Financial Officer & Treasurer
•30+ yrs in finance & deal making in the healthcare industry
•Healthagen, ActiveHealth Management, Cadent Holding, MIM Corporation (Bioscrip), Vital Signs, Zenith/Goldline Pharmaceutical, Coopers & Lybrand
Jane Houldsworth, Ph.D. Vice President of R&D
•25+ years in translational oncology research
•Published 50+ articles, 4 patents
•NIH grantee
John Pappajohn [Chairman of the Board]
|
Keith Brownlie, CPA
|
Edmund Cannon
|
Raju Chaganti, Ph.D.
Michael J. Welsh, M.D.
|
Franklyn Prendergast, M.D., Ph.D.
|
Paul Rothman, M.D.
|
Panna Sharma
Board of Directors
Officers & Management Team

Thank you.
For further information, please contact us at ir@cgix.com
Cancer Genetics, Inc.
Meadows Office Complex
201 Route 17 North
Rutherford, NJ 07070
(201) 528-9200
www.cancergenetics.com

Cgix presentation red chip

More Related Content

What's hot

Similar to Cgix presentation red chip

More from RedChip Companies, Inc.

Cgix presentation red chip